How sunitinib affects blood vessel function
Molecular mechanisms of translational control in sunitinib-induced vascular dysfunction
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11050421
This study is looking at how the cancer medication sunitinib affects the blood vessels in patients, especially how it changes the cells that line those vessels, to help understand why some people might have heart problems while taking the drug.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11050421 on ClinicalTrials.gov |
What this research studies
This research investigates how sunitinib, a medication used to treat certain cancers, impacts the function of blood vessels. It focuses on the role of endothelial cells, which line the blood vessels, and how their behavior changes in response to sunitinib treatment. By examining the molecular mechanisms involved, the study aims to uncover why some patients experience vascular dysfunction and cardiac issues while on this medication. The approach includes analyzing gene expression and protein production in endothelial cells under stress conditions induced by sunitinib.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors, particularly metastatic renal cell carcinoma, who are being treated with sunitinib.
Not a fit: Patients who are not receiving sunitinib or those with conditions unrelated to vascular dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of vascular side effects in patients undergoing treatment with sunitinib.
How similar studies have performed: Other research has shown that understanding the molecular mechanisms of drug-induced vascular dysfunction can lead to better therapeutic strategies, indicating potential success for this approach.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ONG, SANG GING — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: ONG, SANG GING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.